Canifarma Says 650–700 Medicine Listings Pulled From Mercado Libre Under Brand-Protection Deal

PHARMA REGULATION · SUPPLY CHAIN INTEGRITY · OCTOBER 22, 2026 · MEXICO

Canifarma (Cámara Nacional de la Industria Farmacéutica y de Dispositivos Médicos), Mexico’s pharmaceutical and medical-device industry chamber, says between 650 and 700 medicine listings have been removed from Mercado Libre since a collaboration agreement it signed with the marketplace in June 2026 took effect, and has warned that medicines and supplies intended for Mexico’s public health sector are being sold on Mercado Libre and Facebook, according to El Economista. The agreement, which covers intellectual property (IP) rights in the pharmaceutical and medical-device sector within the marketplace, gives Canifarma access to Mercado Libre’s Brand Protection Program, through which the chamber can monitor listings and file complaints on behalf of affiliated companies against products that infringe IP rights.

Alejandro Córdova, Canifarma’s director of supply and coordinator of its Security and Supply Chain Commission, said products being sold this way include items whose packaging carries the legend “Propiedad del Sector Salud, prohibida su venta” (Property of the Health Sector, sale prohibited), and described the problem as the diversion of institutional product. On Facebook Marketplace, he said, it is very difficult to trace who is selling and how, according to El Economista.

The significance of the agreement lies in what it signals about the integrity of digital pharmaceutical commerce in Mexico. Medicines and medical devices sold without authorization or in violation of IP rights on consumer-facing digital marketplaces present risks to patients and to manufacturers whose labels may appear on non-genuine products. For manufacturers supplying public tenders, the exposure is reputational and operational: product bearing their labels may reach patients outside validated storage conditions, without the dispensing oversight that a licensed pharmacy provides.

A supply chain under pressure

Mexico’s institutional drug-supply system has faced documented stress. President Claudia Sheinbaum announced in May 2025 a decree to incentivize international pharmaceutical companies — from India, the United States, and Europe — to manufacture medicines inside Mexico, citing the high cost of imports to the state, according to El País. Sheinbaum also said she wanted to strengthen Birmex (Laboratorios de Biológicos y Reactivos de México), the state company in charge of procurement, which El País noted has faced irregularities. That context matters: a procurement system under documented strain is one in which supply-chain integrity is structurally under pressure.

The digital marketplace dimension adds a layer of regulatory complexity. Colombia’s Instituto Nacional de Vigilancia de Medicamentos y Alimentos (INVIMA), the national medicines and food surveillance body, has applied monitoring to e-commerce channels: INVIMA’s observatory, in its most recent published data, recorded 18,269 e-commerce publications reported or suspended across all regulated product categories; 130 involved chemical-synthesis medicines and 56 biological medicines. In Mexico, online sale of medicines falls under the Comisión Federal para la Protección contra Riesgos Sanitarios (COFEPRIS), the federal health-risk regulator — but enforcement against informal listings on general-purpose marketplaces presents a different operational challenge than regulating licensed pharmacy websites.

Mercado Libre’s position is structurally notable. Fernando Yunes, executive vice president of commerce at Mercado Libre, stated in March 2026 that medicines are ‘the only commerce category in which we do not operate in Brazil,’ and that a pilot to bring medicines onto the platform was imminent, according to Exame. In Mexico, Argentina, Chile, and Colombia, Mercado Libre already sells medicines with and without prescription, Yunes noted. The Canifarma brand-protection agreement on Mercado Libre’s Mexican platform — where the company does operate in the pharmaceutical category — reflects the growing importance of IP enforcement as the company expands its pharmaceutical footprint across Latin America.

Patient safety and the traceability gap

For patients, the risk from non-genuine or unauthorized medicines is concrete. Products sold outside licensed channels arrive without the dispensing controls, pharmacist oversight, or cold-chain verification that licensed retail pharmacies are required to maintain. Buyers on a general-purpose platform generally cannot verify batch provenance, expiry status, or storage integrity at the point of sale.

For the pharmaceutical industry, the operational implication is a pressure to strengthen serialization and traceability. If a manufacturer’s product can be traced only to the moment it enters the government warehouse, and not through to the patient, the chain of custody is incomplete; Canifarma’s Alejandro Córdova has said traceability in the public channel is complicated because it implies additional costs, and that institutional product is being diverted to online sale.

The deeper signal is that digital marketplaces have become a diagnostic tool for supply-chain integrity: the Canifarma-Mercado Libre agreement reflects an industry recognition that brand protection in e-commerce requires active, institutionalized monitoring — not only reactive enforcement after products have already reached consumers.

Medicines and E-Commerce: Key Milestones

Why this is relevant

Sources: El Economista: Detectan venta de medicamentos e insumos del sector salud en Mercado Libre y Facebook · El Economista: Mercado Libre y Canifarma acuerdan proteger la propiedad intelectual en la industria farmacéutica · INVIMA: Denuncias de comercio electrónico · Exame: Queremos avançar com medicamentos no Mercado Livre este ano, diz Yunes · El País: Sheinbaum busca incentivos para que las farmacéuticas inviertan en la producción de medicinas en México